This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Salix Pharmaceuticals Ltd.
Salix Pharmaceuticals Ltd., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal disorders. Founded in 2001, the company has made significant strides in developing innovative therapies that address unmet medical needs, particularly in the areas of irritable bowel syndrome and inflammatory bowel disease. Salix is renowned for its core products, including prescription medications that offer unique mechanisms of action, setting them apart in a competitive market. With a strong commitment to research and development, Salix has achieved notable milestones, solidifying its position as a leader in gastrointestinal health. The company continues to expand its operational reach, serving patients across North America and beyond, while maintaining a focus on delivering high-quality, effective treatments.
DitchCarbon Score
How does Salix Pharmaceuticals Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Salix Pharmaceuticals Ltd.'s score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Salix Pharmaceuticals Ltd., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Bausch Health Companies Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges specific to Salix Pharmaceuticals, it is important to note that any potential climate initiatives or targets would likely be aligned with those set by its parent company, Bausch Health Companies Inc. This includes commitments to sustainability and emissions reduction that may cascade down to Salix Pharmaceuticals. As of now, Salix Pharmaceuticals has not disclosed any specific initiatives or targets related to the Science Based Targets initiative (SBTi) or other industry-standard climate frameworks. The lack of emissions data and reduction commitments highlights an opportunity for the company to enhance its environmental accountability and transparency in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Salix Pharmaceuticals Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
